PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$2.06 USD
-0.22 (-9.45%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.06 0.00 (0.00%) 7:08 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PROK 2.06 -0.22(-9.45%)
Will PROK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PROK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROK
Play Likely Earnings Beat With 3 Top-Ranked Stocks
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
PROK: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for PROK
ProKidney initiated with bullish view at Guggenheim, here's why
ProKidney price target lowered by $1 at BofA, here's why
Maintaining Hold on ProKidney Amid Strategic Shifts and Regulatory Uncertainties
ProKidney’s Hold Rating Maintained Amid Financing and Clinical Uncertainties
ProKidney revises Phase 3 program for lead asset